Apnimed Plans $160 Million IPO for Sleep Apnoea Treatment Development
Apnimed is set to launch an initial public offering (IPO) on the Nasdaq, aiming to raise up to $160 million to support the development of its innovative therapy for obstructive sleep apnoea (OSA). The company, based in Massachusetts, plans to offer 10 million shares priced between $14 and $16 each, with the possibility of increasing this amount by an additional 1.5 million shares, potentially generating an extra $24 million depending on underwriter interest.
The funds raised from the IPO will primarily be allocated to advancing Apnimed's lead candidate, oxnimbi, also known as AD109, which is designed to enhance muscle activity in the upper airways to prevent airway collapse during sleep. Apnimed intends to dedicate approximately $228.8 million from the IPO and existing resources to support the regulatory process and commercialization efforts for oxnimbi. Additionally, some of the IPO proceeds will be used to fund research and development activities for other drug candidates.
For Your Trading Desk
Sponsor Spike Success.
Currently, oxnimbi is under review by the U.S. Food and Drug Administration (FDA), which is expected to make a decision on its approval by February 28, 2027, based on positive data from the drug's Phase III clinical trials. While there are various device-based treatments available for OSA, many patients are either ineligible for or unwilling to use continuous positive airway pressure (CPAP) machines, which are designed to keep airways open during sleep.
If approved, oxnimbi would be the first oral therapy available for OSA, a market that has seen limited pharmaceutical options until recently. In 2024, Eli Lilly's weight loss drug, Zepbound (tirzepatide), became the first medication to receive approval for OSA, providing a new treatment avenue for obese patients. However, a review published in Sleep Medicine noted that only about one-third of OSA patients are clinically obese, indicating a significant portion of patients may not benefit from Zepbound.
By introducing a treatment suitable for all types of OSA, regardless of a patient's weight, Apnimed aims for oxnimbi to become a leading option in the market, which currently affects approximately 936 million individuals globally. Apnimed's CEO, Larry Miller, expressed optimism about the potential of oxnimbi to reshape the sleep apnoea treatment landscape and create significant commercial opportunities for the company.




